Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Subjects With Parkinson's Disease

Next Previous
X
Search
Trial Profile

A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Subjects With Parkinson's Disease

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DNL-151 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Biogen

    • Most Recent Events

    • 18 Feb 2023 Results of pooled analysis from (DNLI-C-0001, DNLI-C-0003) assessing to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the potent, selective, CNS-penetrant LRRK2 inhibitor BIIB122 (DNL151) in healthy participants and patients with PD published in the Movement Disorders
    • 22 Sep 2021 Results assessing safety, tolerability, pharmacokinetics and pharmacodynamics of DNL151 from two phase 1 clinical studies: DNLI-C0001 and DNLI-C0003 presented at the 25th International Congress of Parkinson's Disease and Movement Disorders
    • 03 May 2021 According to a Denali Therapeutics media release, results from this study were presented at the International Association of Parkinsonism and Related Disorders Virtual Congress 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top